{"chunk":"Process Validation\nCompounding Quality Center of Excellence\nAnnual Conference\nSeptember 13, 2023\nNeda Hamandi\nTeam Lead, Office of Compounding Quality and Compliance\nwww.fda.gov\nDisclaimer\nThe information in this presentation was obtained from several resources, including but not limited to:","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\u2022 eCFR :: 21 CFR Part 211 -- Current Good Manufacturing Practice for Finished Pharmaceuticals\n\u2022 FDA Final Guidance for Industry, Process Validation: General Principles and Practices (January 2011)\n\u2022 FDA Guidance for Industry PAT \u2013 A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\u2022 FDA Guidance for Industry Q8(R2) Pharmaceutical Development*\n\u2022 FDA Guidance for Industry Q9 Quality Risk Management*\n\u2022 FDA Guidance for Industry Q10 Pharmaceutical Quality System*\n\u2022 FDA Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP regulations","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\u2022 Current Good Manufacturing Practice\u2014Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C\nAct Guidance for Industry | FDA (Draft Guidance)\n\u2022 PDA TR60: Process Validation\n* Note: The ICH documents have been adopted by FDA and additional information on ICH documents can be found in FDA guidance for","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"industry documents.\nwww.fda.gov www.fda.gov\nAgenda\n\uf0d8 Laws, Regulations, and Guidance\n\uf0d8 PV Life Cycle Approach\n\uf0d8 Stages of Process Validation\n\uf071Stage 1\n\uf071Stage 2\n\uf071Stage 3\n\uf0d8 Change Management\nwww.fda.gov www.fda.gov\nProcess Validation\nPV is defined as the collection and evaluation of data, from the Process","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Design stage through commercial production, which establishes\nscientific evidence that a process is capable of consistently delivering\nquality products.\nPV involves a series of activities taking place over the lifecycle of the\nproduct and process.\nFDA Final Guidance for Industry, Process Validation: General Principles\nand Practices (January 2011)","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"www.fda.gov www.fda.gov\nLaws, Regulations, Guidance, and Best Practices\nItems Descriptions\nLaws (Statutes) The Federal Food, Drug and Cosmetic (FD&C) Act is a federal law (statute) enacted by\nCongress. Federal laws establish the legal framework within which FDA operates. The","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"FD&C Act can be found in the United States Code (U.S.C), which contains all general and\npermanent U.S. laws, beginning at 21 U.S.C. 301.\nRegulations FDA develops regulations (e.g., current good manufacturing practice (CGMP)\nrequirements) based on the statutes such as the FD&C Act or other laws under which","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"FDA operates. FDA regulations are also federal laws, but they are not part of the FD&C\nAct. FDA regulations can be found in Title 21 of the Code of Federal Regulations (CFR).\nGuidance FDA follows the procedures required by its \"Good Guidance Practice\u201c regulation to issue","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"FDA guidance. FDA guidance describes the agency\u2019s current thinking on a regulatory\nissue. In general, FDA guidance is not legally binding on the public or FDA.\nStandards and Best Practices Standards are internationally agreed upon principles by experts; best practices are\nprocedures or processes shown by research and experience to produce optimal","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"results and is established or proposed as a standard suitable for widespread adoption.\nBest practices are recommendations and not legally binding.\nwww.fda.gov www.fda.gov\nProcess Validation in the Regulations\n\u00a7 211.100 Written procedures; deviations\na) There shall be written procedures for production and process control","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"designed to assure that the drug products have the identity, strength,\nquality, and purity they purport or are represented to possess. Such\nprocedures shall include all requirements in this subpart. These written\nprocedures, including any changes, shall be drafted, reviewed, and\napproved by the appropriate organizational units and reviewed and","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"approved by the quality control unit.\nb) Written production and process control procedures shall be followed in\nthe execution of the various production and process control functions\nand shall be documented at the time of performance. Any deviation\nfrom the written procedures shall be recorded and justified.\nwww.fda.gov www.fda.gov","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Stages of Process Validation\nStage 1\nProcess Design\nEvaluate \/ Confirm\nStage 2\nProcess Qualification\nChanges\nDesign of Facilities\nand Qualification of\nEquipment and\nUtilities\nProcess\nPerformance\nQualification\nChanges\nDistribute\nDistribute\nStage 3\nContinued Process Verification\nwww.fda.gov www.fda.gov\nGeneral Elements for Successful PV","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"1. An integrated team approach to PV, as appropriate to the size and\nscale of your organization, is recommended. Teams are composed of\nexperts from a variety of disciplines.\n2. All studies should be planned and conducted according to sound\nscientific principles, appropriately documented, and approved in","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"accordance with the established procedure appropriate for the stage\nof the lifecycle.\n3. The degree of control for process operations and process\nparameters should be commensurate with their risk of impacting the\ndesired product quality attributes or in-process specifications.\nwww.fda.gov www.fda.gov\nLifecycle Approach to Process Validation","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Stages Parts\nStage 1\nProcess Design\nPart I: Building and Capturing Process\nKnowledge and Understanding\nPart II: Establishing a Strategy for Process Control\nStage 2\nProcess Qualification\nPart I: Design of a Facility and Qualification of\nUtilities and Equipment\nPart II: Process Performance Qualification\nStage 3\nContinued Process Verification (CPV)","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Initial CPV Planning\nShort Term CPV\nLong Term CPV\nwww.fda.gov www.fda.gov\nLifecycle Approach to Process Validation:\nStage 1, Process Design\n\u2022 Part I: Building and Capturing Process Knowledge and\nUnderstanding\n\u2022 Part II: Establishing a Strategy for Process Control\nwww.fda.gov www.fda.gov\nStage 1, Process Design \u2013 Overview","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"The goal of this stage is to design a process suitable for commercial\nproduction that consistently delivers a product that meets its pre-\ndefined quality attributes. Process Design defines the commercial\nproduction process that will be documented in the master production\nand control records.","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"It is important to recognize that quality cannot be tested into products\n(i.e., quality is built in by design).\nwww.fda.gov www.fda.gov\nLifecycle Approach to Process Validation\nStage 1, Process Design\nPart I: Building and Capturing Process Knowledge and Understanding\nwww.fda.gov www.fda.gov\nPart I of Stage 1:","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Part I of Stage 1:\nBuilding and Capturing Process Knowledge and Understanding\n\uf0d8 Establish Quality Target Product Profile (QTPP), Critical Quality\nAttributes (CQA), Critical Process Parameters (CPP), Critical\nMaterial Attributes (CMA)\n\uf0d8 Perform Quality Risk Management\n\uf0d8 Define the Manufacturing Process\n\uf0d8 Perform Process Characterization","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"www.fda.gov www.fda.gov\nEstablish QTPP, CQA, CPP, CMA\nQuality Target Product Profile, QTPP, is a summary of the quality characteristics of a\nfinished drug product (like purity, sterility, stability, route of administration, dosage form,\nand strength) that ideally will be achieved to ensure the desired quality and strength of the\ndrug product.","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"drug product.\nA Critical Quality Attribute, CQA, is a physical, chemical, biological, or microbiological\nproperty or characteristic that must be within an appropriate limit, range, or distribution\nto ensure the desired product quality (ICH Guidance for Industry Q8(R2) Pharmaceutical\nDevelopment).","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Development).\nA Critical Process Parameter, CPP, is a process parameter whose variability has an impact\non a CQA, and therefore should be monitored or controlled to ensure the process\nproduces the desired quality (ICH Guidance for Industry Q8(R2) Pharmaceutical\nDevelopment).","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Development).\nCritical Materials: Raw materials (e.g., Bulk Drug Substance (BDS) or excipients), finished\nproduct containers, and closures are critical materials. Specifications must be established\nfor critical materials. These specifications are referred to as Critical Material Attributes\n(CMAs).\nwww.fda.gov www.fda.gov","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Relationship Between CMAs, CPPs, and CQAs\nCPPs\nCMAs CQAs\nManufacturing Unit\nOperation\nInput Materials Output Materials\nor Product\nwww.fda.gov www.fda.gov\nPart I of Stage 1:\nBuilding and Capturing Process Knowledge and Understanding\n(1 of 3)\n\uf0d8 Establish QTPP, CQA, CPP, CMA\n\uf0d8Perform Quality Risk Management\n\uf0d8 Define the Manufacturing Process","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\uf0d8 Perform Process Characterization\nwww.fda.gov www.fda.gov\nQuality Risk Management (QRM)\n\uf0d8 QRM is a systematic process for the assessment, control, communication, and review of risks to\nthe quality of the drug product across the product lifecycle. The application of risk management","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"principles and approaches is instrumental to effective decision-making in selecting the correct\nCQAs and CPPs (PDA TR60).\n\uf0d8 Risk assessment should occur early in the Design Stage and consciously be assessed, controlled, and communicated throughout the lifecycle of the finished drug product.","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\uf0d8 With a lifecycle approach to PV that employs risk-based decision-making throughout the\nlifecycle, the perception of criticality as a continuum rather than a binary state is useful.\n\uf0d8 All attributes and parameters should be evaluated in terms of their roles in the process and","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"impact on the product or in-process material and reevaluated as new information becomes\navailable.\n\uf0d8 The degree of control over those attributes or parameters should be commensurate with their\nrisk to the process and process output. In other words, a higher degree of control is appropriate","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"for attributes or parameters that pose a higher risk to the process and process output.\nHigher\nRisk\nHigher Degree of\nControl\nwww.fda.gov www.fda.gov\nICH Q9 Risk Management Framework*\nInitiate QRM Process\nRisk Assessment\nHazard Identification\nRisk Analysis\nRisk Communication\nRisk Evaluation\nUnacceptable\nRisk Control\nRisk Reduction\nRisk Acceptance","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Risk Acceptance\nRisk Management Tools\nOutput \/ Result of the QRM Process\nRisk Review\nReview Events\n*Figure 1: Overview of a typical quality risk management process from Q9(R1) Guidance\nwww.fda.gov www.fda.gov\nPart I of Stage 1:\nBuilding and Capturing Process Knowledge and Understanding\n(3 of 3)\n\uf0d8 Establish QTPP, CQA, CPP, CMA","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\uf0d8 Perform Quality Risk Management\n\uf0d8Define the Manufacturing Process\n\uf0d8 Perform Process Characterization\nwww.fda.gov www.fda.gov\nDefine the Manufacturing Process\nLevel of Detail\n\uf0fcProcess requirements, including raw materials and order of operations\n\uf0fcSet points and ranges for the process parameters","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\uf0fcIdentification and quantity of all material flows (e.g., additions, wastes, product streams)\n\uf0fcTesting, sampling, and in-process controls (IPCs)\n\uf0fcHold times and hold conditions for product and additional solutions\n\uf0fcMaterials reconciliation\n\uf0fcEstimated step yields and durations","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\uf0fcSizing for equipment, including such items as mixers or filtration units (e.g., filter surface area, filter volume, and pore size)\n\uf0fcSpecific identification (i.e., manufacturer, part number) for manufacturing (e.g., filters) and packaging components (e.g., vials, stoppers)\n\uf0fcOther information necessary to successfully reproduce the process","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\uf0fc Actual and theoretical yields\nwww.fda.gov www.fda.gov\nPart I of Stage 1:\nBuilding and Capturing Process Knowledge and Understanding\n(2 of 3)\n\uf0d8 Establish QTPP, CQA, CPP, CMA\n\uf0d8 Perform Quality Risk Management\n\uf0d8 Define the Manufacturing Process\n\uf0d8Perform Process Characterization\nwww.fda.gov www.fda.gov\nProcess Characterization","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\uf0d8 Process Characterization is a set of documented studies in which operational\nparameters are purposely varied to determine their effect on product quality\nattributes and process performance.\n\uf0d8 The output of process design and characterization is a strategy for process control, which is Part II of Stage I of Process Design.","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\uf0d8 Process design and characterization should be conducted in accordance with\nsound scientific methods and principles, including good documentation\npractices (GDP).\n\uf0d8 Process information available from literature sources (e.g., compounding\nformulations or recipes, United States Pharmacopeia (USP) monographs) or","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"similar production processes already used can be leveraged to design and\ncharacterize production processes for new products.\nwww.fda.gov www.fda.gov\nLifecycle Approach to Process Validation (1 of 3)\nPart II: Establishing a Strategy for Process Control\nwww.fda.gov www.fda.gov\nStage 1 Part II: Establishing a Strategy for Process Control","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\uf0d8Categorization of Parameters and Establishment of Control\nStrategy\n\uf0d8 System Classifications \/ Boundaries (Direct vs. Indirect Impact\nSystems Based on CQAs and CPPs)\nwww.fda.gov www.fda.gov\nProcess Control Strategy\nA process control strategy is a planned set of controls, derived from\nproduct and process understanding, which ensures process","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"performance and product quality.\nwww.fda.gov www.fda.gov\nElements of a Process Control Strategy\nA robust process control strategy encompasses all unit operations in the process. All product quality\nattributes and process parameters, regardless of whether they are classified as critical, are included","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"in a comprehensive process control strategy, which includes the elements detailed below:\n\uf0fcFacility\n\uf0fcPersonnel\n\uf0fcRaw Material Controls\n\uf0fcProcess Parameters (Set Points and Ranges)\n\uf0fcProcess Monitoring (Data Review, Sampling, Testing)\n\uf0fcIn-Process and Release Specifications\n\uf0fcProcessing Times\n\uf0fcHold Times\n\uf0fcContainers and Closures Control","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"www.fda.gov www.fda.gov\nProcess Parameters (Set Points and Ranges)\nProven Acceptable Range (PAR)\nNormal Operating Range (NOR)\nSet Point\nObservation\nAlert Limit Observation\nDiscrepancy\nDiscrepancy\nAction Limit\nwww.fda.gov www.fda.gov\nStage 1, Part II: Establishing a Strategy for Process Control","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\uf0d8 Categorization of Parameters and Establishment of Control Strategy\n\uf0d8 System Classifications \/ Boundaries (Direct vs. Indirect Impact\nSystems Based on CQAs and CPPs)\nwww.fda.gov www.fda.gov\nSystem Classification: Direct and Indirect Impact Systems\nDirect Impact Systems\nIndirect Impact Systems","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\u2022 Directly impact CQAs and \/ or CPPs, and therefore have direct\nimpact on process and product quality.MP control.\n\u2022 Should be commissioned and qualified.\nDirect Impact System operations are often recorded in batch\nrecords such as filling equipment and sterilization equipment (e.g.,\nblenders, mixers, filters, autoclaves, depyrogenation ovens).","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\u2022 May be referred to as indirect impact, no impact, process non-\ncritical, etc.\n\u2022 Systems that do not directly impact any CPPs and CQAs and,\ntherefore, have no direct relationship to process and product\nquality, and\n\u2022 Require less scrutiny.\n\u2022 Will only be commissioned.\nBased on need, some processes may be commissioned, but not","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"qualified. For example, heating, ventilation, and air conditioning\n(HVAC) for the office space.\nTheir data will not be recorded in the batch \/ production record;\nhowever, a catastrophic failure on their part could impact the\nDirect Impact Systems they support.","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"System Boundaries define at which point the indirect systems end and the direct systems begin.\nwww.fda.gov\nComputer and Electronic Systems\nComputerized and electronic systems used for production applications are\nqualified per 21 CFR part 11 and Data Integrity and Compliance with Drug CGMP","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Questions and Answers Final Guidance for Industry and EU Annex 11.\nQualification criteria include, but are not limited to:\n\u2022 Specificity\n\u2022 Accuracy\n\u2022 Data management\n\u2022 Sensitivity\n\u2022 Communication\n\u2022 Electronic integration requirements of information technology compatibility\nwww.fda.gov www.fda.gov\nSummary of Stage 1 Process Design","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"The representative list below summarizes the information needed to transition from Stage 1 (Process Design) to Stage 2 (Process Qualification) in the PV lifecycle.\n\u2022 Quality Target Product Profile\n(QTPP)\n\u2022 Critical Quality Attributes (CQAs)\n\u2022 Quality Risk Assessment\n\u2022 Critical Process Parameters\n(CPPs)\n\u2022 Manufacturing Process Design","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\u2022 Analytical Methods\n\u2022 Process Characterization\n\u2022 Process Validation Master Plan\n\u2022 Process Control Strategy\n\u2022 Manufacturing Technology\n\u2022 Documentation Development\nProcess\nValidation\nProcess Improvement \/ Optimization\nUpdated\nMaster Batch Record\nMaster Batch Record\nwww.fda.gov\nChange Control\nLifecycle Approach to Process Validation","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Stage 2: Process Qualification\n\u2022 Part I: Design of a Facility and Qualification of Utilities and\nEquipment\n\u2022 Part II: Process Performance Qualification\nwww.fda.gov www.fda.gov\nStage 2, Part I\nDesign of a Facility and Qualification of Utilities and Equipment\n\uf0d8 Commissioning, Factory Acceptance Test (FAT), and Site Acceptance Test (SAT)","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\uf0d8 Qualification\n(PQ)\n\uf071 Installation Qualification (IQ), Operation Qualification (OQ), and Performance Qualification\nwww.fda.gov www.fda.gov\nUnderstanding and Leveraging Commissioning,\nFAT, and SAT\nCommissioning\nCommissioning verifies the facility, utility, and equipment (the \u201csystem\u201d) are installed properly, function","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"properly, have the proper utilities connected correctly, (e.g., are the fans blowing in the right direction?), are\naccessible (e.g., can I get to sampling points, or can I get the HEPA filter changed if it is installed too close to the\nwall?), and thus was successfully turned over to the end user. Commissioning, when executed properly, is","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"important to support the success of the subsequent qualification activities.\nFAT\nFAT provides documented evidence a piece of equipment or system has been adequately tested at the\nmanufacturer\u2019s facility and performs to the end user\u2019s expectations prior to delivery to the end user. FAT is not","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"mentioned or discussed in the FDA PV guidance, but it provides an opportunity to head off problems by\nfinding any issues while it is still in the factory where it can be corrected more easily.\nSAT\nSAT provides documented evidence a piece of equipment or system has not been affected in the","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"transportation and has been adequately tested at the end user\u2019s facility and performs to the end user\u2019s\nexpectations. SAT is not mentioned or discussed in the FDA PV guidance, but it provides an opportunity to\narrange for either factory representatives or supplier service personnel to participate in the first start-up and","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"tests, and for the receiving site\u2019s personnel to ask them questions.\nwww.fda.gov www.fda.gov\nStage 2, Part I : Design of a Facility and Qualification of\nUtilities and Equipment\n\uf0d8 Commissioning, Factory Acceptance Test (FAT), and Site Acceptance Test (SAT)\n\uf0d8 Qualification","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\uf0d8 Qualification\n\uf071 Installation Qualification (IQ), Operation Qualification (OQ), and Performance\nQualification (PQ)\nwww.fda.gov www.fda.gov\nQualification (IQ \/ OQ \/ PQ) of Equipment and Systems\nInstallation Qualification (IQ)\nIQ provides documented verification all aspects of a facility, utility, or equipment that can affect","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"product quality (i.e., critical) adhere to approved specifications as defined in the URS (e.g., materials\nof construction) and are correctly installed.\nOperational Qualification (OQ)\nOQ is the documented verification the facilities, systems, and equipment, as installed or modified,\noperate as intended throughout the anticipated operating ranges.","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Performance Qualification (PQ)\nPQ is the documented evidence that provides a high degree of assurance the equipment and\nsystems function accurately and consistently according to predetermined specifications within the\noperating ranges defined in Stage 1 in its operating environment.\nwww.fda.gov www.fda.gov\nQualification Throughout the Lifecycle","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"After the successful qualification of the equipment and systems in the manufacturing facility, it is important to ensure\nthe equipment and systems are maintained in a state of control and operate in a manner consistent with their qualified\nstate throughout the product lifecycle.\nThis is done by:\nPreventive Maintenance","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Maintenance is performed routinely according to a defined schedule (e.g., the certification of HEPA filters every six\nmonths).\nPredictive Maintenance\nIndividual(s) assigned the responsibility to maintain equipment take advantage of available information, forecast\npossible failures, and take maintenance action before a failure occurs.\nCalibration","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Calibration\nA calibration program assures data collected from instruments and devices are both precise and accurate within the\nacceptable range. Periodic and annual calibration should be incorporated into the calibration program (may also be part\nof a preventive maintenance program).\nRequalification","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Requalification\nRequalification may be required whenever qualified systems have been changed or modified. The extent and impact of\nthe change must be evaluated for their impact on the original qualification. Requalification is also routinely performed","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"on a periodic basis to ensure that systems continue to operate in their qualified state throughout the lifecycle of the\nproduct. How often a system will need to be requalified will depend on the criticality of that system.\nwww.fda.gov www.fda.gov\nSummary of PV Stage 2: Part I","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"The typical system qualification sequence is displayed in the figure below.\nEngineering\nInstallation\nStart-up\nSystem\nQualification\n\/ Verification\nStep 1: Transfer Process Design requirements and CPP information\nfrom Stage 1 Process Design\nStep 2: Review to confirm system design (i.e., URS) is aligned with\nDesign Perform system risk or","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"process requirements\nimpact assessment to\ndetermine which systems\nConstruction,\nFabrication,\nInstallation\nStep 3: Perform FAT and SAT to confirm the system meets design\nand system elements are\nspecification\ncritical to product quality\nCommissioning\nTesting\nStep 4: Perform commissioning studies to confirm systems are in\nreliable working order","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Step 5: Evaluate information obtained during commissioning to\ndetermine what can be leveraged during qualification\nStep 6: Perform qualification studies (IQ \/ OQ \/ PQ) to ensure that\nsystems are capable of meeting process requirements\nDevelop Qualification\nProtocol, including test\nfunctions and acceptance\ncriteria, based on process","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"requirements and system\ncapabilities\nStep 7: Evaluate qualification results and release system for PPQ\nwww.fda.gov www.fda.gov\nLifecycle Approach to Process Validation (2 of 3)\nStage 2: Process Qualification\nPart II: Process Performance Qualification\nwww.fda.gov www.fda.gov\nProcess Performance Qualification, PPQ","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"PPQ combines the qualified facility, utilities, and equipment and trained personnel with the\ncommercial manufacturing process, control procedures, and components to produce the PPQ\nbatches. The goal of PPQ is to establish scientific evidence that the commercial production process\nis reproducible and will consistently deliver quality products.","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"www.fda.gov www.fda.gov\nPV Stage 2, Part II: Process Performance Qualification, PPQ\nPrepare for PPQ\nReadiness\nAssessment\nPrepare for PPQ by reviewing the status of activities required to be completed prior\nto commencement of the PPQ batches.\nDevelop Strategy and\nApproach\nDesign PPQ based on multiple considerations specific to the manufacturing","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"process and determine the number of manufacturing runs and sample plan.\nDesign of PPQ\nCompile PPQ\nProtocol\nDocument all of the necessary elements in the PPQ protocol, including pre-\ndetermined acceptance criteria.\nExecute the Process\nExecute PPQ\nProtocol\nPerform the procedures as outlined in the PPQ protocol, including manufacturing","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"steps and testing of analytical samples.\nAnalyze PPQ Results\nAgainst Acceptance\nCriteria\nAnalyze Results and\nCompile PPQ Report\nAnalyze the data obtained during PPQ following statistical methodology and\nacceptance criteria from the PPQ protocol and address deviations and failures.\nwww.fda.gov www.fda.gov","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Analyze PPQ Results Against Acceptance Criteria\nSections of the PPQ Report\nThe PPQ report will typically include the following sections:\n\u2022 Summary\n\u2022 Deviations\n\u2022 Methods and Materials\n\u2022 Conclusions\n\u2022 PPQ Results\n\u2022 Approvals\nwww.fda.gov www.fda.gov\nAseptic Process Simulation (Media Fills) Where Does It Fit?","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\u2022 An aseptic process simulation (APS) is designed to evaluate whether processes may pose\na risk to product sterility are adequately controlled.\n\u2022 The terms \u201caseptic process simulation\u201d and \u201cmedia fills\u201d are often used interchangeably.\n\u2022 APS does not equal process validation; it is a component of process validation.","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\u2022 APS is narrower in focus than PV in that the goal is primarily microbiological.\nqualification \u2013 can product be made that is free from microbial contamination.\n\u2022 APS can be done before or after PPQ. There are pros and cons to both.\n\u2022 A media fill has to be completed before a firm releases any aseptically filled products.","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\u2022 The FDA Compounding Quality Center of Excellence offers a free, self-guided on-line\ncourse available here: Aseptic Process Simulations.\nwww.fda.gov www.fda.gov\nLifecycle Approach to Process Validation (3 of 3)\nStage 3: Continued Process Verification\n\u2022 Initial CPV Planning\n\u2022 Short Term CPV\n\u2022 Long Term CPV\nwww.fda.gov www.fda.gov","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Stage 3: Continued Process Verification (CPV)\nCPV provides ongoing assurance that during routine production the process\nremains in a state of control.\nSource: FDA Final Guidance for Industry, Process Validation: General Principles and Practices (January 2011)\nwww.fda.gov www.fda.gov\nKey Elements of CPV","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Key Elements of CPV\n\u2022 Collect data (e.g., process parameters, test results)\n\u2022 Analyze and review data\n\u2022 Review trends and evaluate process performance\n\u2022 Identify problems and determine whether action must be taken to\ncorrect undesirable variation in the production, process, deviations,\nor failures","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"or failures\n\u2022 Ensure process remains in a state of control throughout the life cycle\n\u2022 Incorporate process improvements\nwww.fda.gov www.fda.gov\nCPV Overview\nInitial CPV Planning\nEstablishes:\n\u2022 Data to include for review and analysis\n(e.g., process parameters, testing\nresults, batch yields)\n\u2022 Elements to measure (e.g., critical","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"process parameters (CPPs), in-process\ncontrols (IPCs), Critical Quality\nAttributes (CQAs), yields)\n\u2022 Sampling plans\n\u2022 Data collection and reporting\n\u2022 Reporting frequency\n\u2022 Data analysis methods (e.g., statistical\ntools, trending methods)\n\u2022 Action plan to respond to out-of-trend\nresults or observed variation\nwww.fda.gov\nOverview of CPV (Stage 3)","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Short-term CPV 6\nIncludes:\n\u2022 Data are collected and reported per\nthe plan.\n\u2022 Control limits, for any of the\nparameters or elements defined in\nthe CPV plan, are created and\nsummarized in a short-term CPV\nreport.\n\u2022 A report and long-term CPV\nplanning are outputs.\nLong-term CPV 7\nIncludes:\n\u2022 Parameters and product attributes","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"(e.g., CQAs, CPPs) are monitored\nand trended.\n\u2022 Reactions to trends are\ncommensurate with the risk\nestablished throughout the PV\nprocess.\n\u2022 Periodic reporting based upon\nfrequency of manufacturing\nQuote\nwww.fda.gov www.fda.gov\nData Collection Plans and Statistical\nProcedures in the PV Lifecyle\nA statistician (or person with","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"adequate training in statistical\nprocess control (SPC))\ntechniques) is recommended\nto develop the data collection\nplan and statistical methods \/\nprocedures used in measuring\nand evaluating process stability\nand process capability.\nCommonly Used Statistical\nProcedures Include:\n\u2022 Run Charts\n\u2022 Individual Value Plots\n\u2022 Tolerance Intervals (TIs)","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\u2022 Variance Components\n\u2022 SPC Charts (I Charts) and\nCapability Analysis\nwww.fda.gov\nExamples of Data Collection Tools: Run Charts\nA run chart is used to study collected data for trends or patterns over a specific\ntime period.\nA run chart will help you:\n\u2022 Monitor data over time to detect trends,\nshifts, or cycles","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"shifts, or cycles\n\u2022 Compare \/ measure data before and after\nthe implementation of a change or corrective\naction to measure impact\n\u2022 Focus attention on important changes (i.e.,\nnot normal variation)\n\u2022 Track useful information for predicting\ntrends.\nX-axis: Units of time by which measurements are made\nY-axis: Attribute being measured","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Centerline: Mean (or average)\nwww.fda.gov\nExamples of Data Collection Tools: Individual Value Plot\nAn individual value plot displays the individual values in each sample to assess\nand compare sample data distributions.\nEach circle represents one reported value,\nmaking it easy to spot outliers and see\ndistribution spread.","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"For example: Batch to batch and sample\npositions within batch.\nX-axis: Inter and intra batches being measured\nY-axis: Attribute being measured\nwww.fda.gov\nProcess Capability\nAbility of a process to produce a product that will fulfill the requirements of\nthat product. A capability study is used to determine whether a process is","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"capable, which involves collecting samples over a period of time and\nanalyzing the samples. There are both complex and simple methods to\nassess capability.\nwww.fda.gov www.fda.gov\nAssessing Process Capability in the\nPV Lifecycle\nExample 1 Example 2 Example 3\nExample 1: Example 2:\nExample 3:\n% %\nSpecification = 90-110%\nwww.fda.gov www.fda.gov","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Control Charts - Examples\nControl Chart\nStrength Values of 30 Lots of Product A Over 1 Year\n120.00\n115.00\nUS\n110.00\n105.00\nUCL\n100.00\nStrength\n95.00\nLCL\n90.00\nLS\n85.00\n80.00\n0 5 10 15 20 25 30 35\nwww.fda.gov www.fda.gov\nControl Chart\nStrength Values of 30 Lots of Product B Over 1 Year\n120.00\n115.00\nUCL\nUS\n110.00\n105.00\n100.00\nStrength\n95.00\n90.00","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"95.00\n90.00\nLS\n85.00\n80.00\nLCL\n0 5 10 15 20 25 30 35\nPV and Change Management\nwww.fda.gov www.fda.gov\nPV and Change Management (cont.)\n\uf0d8 Change management is a systematic approach to proposing, evaluating, approving, implementing, and reviewing changes.*","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\uf0d8 Before changes are implemented, proposed changes should be evaluated by teams composed of people with a diverse background, including ones familiar with the change at issue (e.g., manufacturing, quality) using pre-established\ncriteria.\n\uf0d8 A description of the planned change, a well justified rationale for the change, an","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"implementation plan, and QU approval must be documented before\nimplementation.\n\uf0d8 Depending on how the proposed change might affect product quality and safety,\nadditional process design and process qualification activities may be warranted.\n\uf0d8 Quality risk management (QRM) should be utilized to evaluate proposed\nchanges.","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"changes.\n*Source: ICH Guidance for Industry Q10 Pharmaceutical Quality System\nwww.fda.gov www.fda.gov\nPV Diagram\nStage 1: Process Design Stage 2: Process Qualification Stage 3: Continued\nProcess Verification\nDesign\nPPQ Protocol Design,\nProcess Design Continued Process\nProcess Qualification\nReview\nExecution, and Report\nVerification","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Verification\nPart II: Establishing a\nStrategy for Process Control\nPart II: Process\nPerformance Qualification\nPart I: Building and Capturing\nProcess Knowledge and\nUnderstanding\nPart I: Design of a Facility and\nQualification of Utilities and\nEquipment\nInitial CPV\nPlanning\nEstablish QTPP,\nCQA, CPP\nCategorization of\nParameters and","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Parameters and\nEstablishment of Control\nStrategy\nCommissioning\nPrepare for PPQ\nPerform Quality\nRisk Assessment\nFAT \/ SAT\nDefine the\nManufacturing\nProcess\nSystem Classifications \/\nBoundaries (Direct vs.\nIndirect Impact Systems\nBased on CQAs and\nCPPs)\nQualification\nObjectives to be Achieved\nShort-Term CPV\nDesign of PPQ\nExecute the\nProcess","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Execute the\nProcess\n(PPQ Protocol)\nLong-Term CPV\nPerform Process\nCharacterization\nIQ \/ OQ \/ PQ\nPVMP and URS\nAnalyze PPQ\nResults Against\nAcceptance\nCriteria\nManage Process\nChanges\nRisk Management\nChange Management\nKnowledge Management\nwww.fda.gov www.fda.gov\nRegulatory Requirements\nRegulatory requirements contained in the CFR include:","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Regulatory Requirements Written Procedures; Deviations Sampling and Testing of In-process Materials and Drug Products Adequate Facilities, Maintenance, and Calibration Control of Microbial Contamination Annual Product Review www.fda.gov www.fda.gov\nCFR\n21 CFR 211.100, and\n211.192\n21 CFR 211.110\n21 CFR 211.42(a), 211.63,\nand 211.68(a)","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"and 211.68(a)\n21 CFR 211.113\n21 CFR 211.180(e)\nICH Guidance\nICH is the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human\nUse. ICH is a joint effort to align regulations in what has become a global environment. The following ICH\ndocuments have been adopted in published FDA guidance documents.","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"\u2022 ICH Q8(R2) Pharmaceutical Development\nThis guidance document on pharmaceutical development defines procedures for linking product and process\ndevelopment planning to the final commercial process control strategy and quality system.\n\u2022 ICH Q9 Quality Risk Management","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"This guidance document describes the use of a risk-based approach to pharmaceutical development and\nmanufacturing quality. These approaches identify and prioritize those process parameters and product quality\nattributes with the greatest potential to affect product quality.\n\u2022 ICH Q10 Pharmaceutical Quality System","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"This guidance document is intended to assist pharmaceutical manufacturers by describing a model for an\neffective quality management system for the pharmaceutical industry, referred to as the Pharmaceutical\nQuality System (PQS). To achieve the goals outlined in this guidance document, it is essential to integrate the","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Process Design into the quality system.\nwww.fda.gov www.fda.gov\nKnowledge Management\nKnowledge management is a \u201csystematic approach to acquiring,\nanalyzing, storing, and disseminating information related to\nproducts, manufacturing processes, and components.\u201d\nSource: ICH Guidance for Industry Q10 Pharmaceutical Quality System\nWhy Is It Important?","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Knowledge management supports how knowledge is acquired, analyzed,\nstored, disseminated, and applied across the PV lifecycle. Information\nshould be consistently maintained, either manually or automatically,\ndepending on the system used by each firm.\nwww.fda.gov www.fda.gov\nIntroduction to Legacy Products","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"Legacy products are existing products currently on the market for which\nsome current PV lifecycle concepts may not have been formally established\nand\/or implemented.\nManufacturers of legacy products can take advantage of the knowledge\ngained from the original process development and qualification work to\ndevelop a pathway for validation.","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"www.fda.gov www.fda.gov\nPathway for Validating Legacy Products\nGap Analysis\nA gap analysis helps to reveal\nwhat elements are\nmissing (e.g., CQAs,\nCPPs, control strategy,\nqualification of a piece of\nequipment) and needed to\ncomplete PV.\nData Analysis and Risk\nAssessment\nData analysis should show the\nproduction process was robust","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
{"chunk":"and reliably operating in a state\nof control.\nThe extent of the validation\nactivities to perform will be\ncommensurate with the overall\nrisk as determined based on\nthe gap analysis and risk\nassessment.\nwww.fda.gov\nStage 3: CPV\nQuestions?\nwww.fda.gov www.fda.gov\nThe End","book":"ocqc_presentations_2023-v10-1of1-process-validation_s508"}
